Medical approaches and future options in chronic active ulcerative colitis

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Purine analogue immunosuppressants are standard for chronic active ulcerative colitis.
• Many patients experience intolerance or relapse despite optimized thiopurine therapy.
• Current treatment optimization strategies include monitoring thiopurine-methyltransferase activity and red blood cell 6-thioguanine levels.

Purpose of the Study:

• To review current and future immunomodulating treatment options for chronic active ulcerative colitis.
• To focus on alternative therapies for patients unresponsive to or intolerant of standard immunosuppression.

Main Methods:

• Literature review of existing treatment modalities.
• Discussion of various immunomodulating approaches.
• Analysis of therapeutic regimens including 6-thioguanine, cyclosporine, tacrolimus, methotrexate, cyclophosphamide, infliximab, interferons, heparin, and leukocyte apheresis.

Main Results:

• A substantial proportion of ulcerative colitis patients do not tolerate or relapse on azathioprine or 6-mercaptopurine.
• Numerous alternative therapeutic regimens exist for refractory cases.
• Many of these alternative treatments have limited evaluation in small, uncontrolled trials.

Conclusions:

• Despite advances, achieving long-term remission in chronic active ulcerative colitis remains challenging for many patients.
• Further research and controlled trials are needed to validate the efficacy of alternative immunomodulating therapies.
• Exploring novel immunomodulating strategies is crucial for improving outcomes in ulcerative colitis management.